Lilly puts its stamp at EHA with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Eli Lilly Eyes Label Expansion For Leukemia Drug - Eli Lilly (NYSE:LLY)

Eli Lilly announces BRUIN CLL-322 success: Jaypirca added to venetoclax and rituximab reduces progression-or-death risk by 45% in relapsed or refractory CLL/SLL. The company plans to seek regulatory label expansion and pursue additional Phase 3 trials, extending therapeutic options for patients with prior BTK-inhibitor exposure.